XNYS · Drug Manufacturers - General
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$29.36+0.44%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
52/100
Moderate
Score components
TickerWhale View
Pfizer scores 52 out of 100 overall, which we rate moderate. Risk is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Valuation
- Risk
What to watch
- Quality & growth
Quality & growth
30%13Weak
- Revenue growth -0.2%
- EPS growth -59.6%
Valuation
25%68Positive
- P/E 38.6
- EV/Sales 3.6
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
#72 by market cap in our coverage · ~75,000 employees · Listed 1951-06-22 · www.pfizer.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#88 / 139sector rank by TickerWhale Score
TickerWhale Score 52 vs sector average 54.6 (-2.6)
Revenue growth (industry)Top 91%
Gross margin (industry)Top 45%
Return on equity (industry)Top 80%
P/E (industry)Cheaper than 50%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
72/100Strong vs universe
Ranks 72nd of 100 covered names on our technical composite — the composite itself scores 70/100 · 25% of the TickerWhale Score
Classic chart indicators
Neutral
3 buy · 3 sell · 2 neutral of 8 votes
TickerWhale rates PFE's technical setup strong — 72nd percentile of the covered universe. Classic chart indicators lean neutral — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
5 / 9constructive
- vs 200-day+9.0%
- vs 50-day+2.0%
Momentum
Mixed
- RSI (14)49 · neutral
- Stochasticbuy
- CCIsell
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength29· trending
- MACD (12,26,9)sell(histogram -0.154)
How the classic verdict is reached
Moving averages (9) agree on buy — 5 buy vs 3 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 3 sell · 2 neutral.
Result — 3 buy vs 3 sell of 8 votes = Neutral. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)38.6
- P/S (TTM)2.6
- P/B2.0
- EV/EBITDA—
- EV/Sales3.6
- PEG—
Profitability & returns
- Gross margin73.2%
- Net margin6.8%
- ROE4.9%
- Debt/Equity0.74
Growth
- Revenue growth (YoY)-0.2%
- EPS growth (YoY)-59.6%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $167.3B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $62.6B | $63.6B | $59.6B |
| Gross profit | $46.5B | $45.8B | $34.6B |
| Operating income | $7.5B | $8.0B | $1.1B |
| Net income | $7.8B | $8.0B | $2.1B |
| EPS (diluted) | $1.36 | $1.41 | $0.37 |
| Free cash flow | $9.1B | $9.8B | $4.8B |
| Cash | $1.1B | $1.0B | $2.9B |
| Total debt | $64.8B | $64.4B | $71.9B |
| Equity | $86.5B | $88.2B | $89.0B |
| Net debt | $63.7B | $63.3B | $69.0B |
| Debt / equity | 0.75 | 0.73 | 0.81 |
| Liabilities / assets | 0.58 | 0.59 | 0.61 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFECurrentPfizer | 52 | 70 | 38.6 | — | 2.0 | 3.6 | $29.36 | +0.44% | -0.2% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.